Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 12, 2025 07:32 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction

Patent publication in Europe strengthens Clearmind’s global IP position and advances strategic focus on addiction treatment Vancouver, Canada, May 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine...
May 12, 2025 07:32 ET | Source: SciSparc Ltd

SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction

TEL AVIV, Israel, May 12, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies...
April 16, 2025 08:30 ET | Source: Autonomix Medical, Inc.

Autonomix Medical, Inc. Granted New European Patent for Proprietary Catheter-Based Technology

New patent underscores breadth of application and expansion opportunities for Company’s catheter-based technology Continued progress with growing global patent portfolio to over 80 issued patents...
January 28, 2025 09:05 ET | Source: Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology

European Patent Office (EPO) grants EU Patent No. EP3583125 B1 covering the Company’s Fully Human Albumin Binding (FHAB®) domain fusion proteins In addition to the U.S. and EU, Sonnet’s global IP...
December 23, 2024 09:00 ET | Source: GRI Bio, Inc.

GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds

– Company committed to building a robust global patent estate across its innovative pipeline of NKT cell modulators LA JOLLA, CA, Dec. 23, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI...
July 19, 2024 08:30 ET | Source: Palisade Bio, Inc.

Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108

Patent includes Composition of Matter claims for both PALI-2108 and PALI-1908 programs Patent includes broad claims for “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors” with similar...
June 23, 2023 08:01 ET | Source: Ocean Biomedical, Inc.

Ocean Biomedical (NASDAQ: OCEA) Extends Patent Rights for Breakthrough Idiopathic Pulmonary Fibrosis Discovery To Europe

Patent notice extends global coverage for breakthrough discovery, with potential for treating Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases, including Scleroderma, Nonalcoholic...
March 01, 2023 09:05 ET | Source: Palisade Bio, Inc.

Palisade Bio Receives Intention to Grant from European Patent Office for LB1148 Patent

Carlsbad, CA, March 01, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a clinical stage biopharmaceutical company advancing therapies for acute and chronic...
February 08, 2023 09:00 ET | Source: BioRestorative Therapies, Inc

BioRestorative Therapies Announces Notice of Allowance by the European Patent Office for Patent Related to its ThermoStem® Program

--Patent provides protection in key international markets for BioRestorative’s ThermoStem® program targeting obesity and metabolic disorders, including type 2 diabetes-- MELVILLE, N.Y., Feb. 08,...
February 21, 2019 08:03 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Receives European Patent Covering its Alzheimer's Disease Candidate, Elayta™

Pittsburgh, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative...

Next Page keyboard_arrow_right